With reference to the Increase in Price, Samrat Pharmachem has clarified that in this connection, they would like to inform you that Company has not made any big announcement having impact on its operation and performance in recent times. The Company has been sharing all information/ announcements that have a bearing on the price/ volume behavior in the script with the stock exchange regularly. The reason for the increase in the price of share on the BSE is not result of any announcement or pending announcement made or to be made by the company. The Company has not shared any price sensitive information with any market intermediary or any other party and therefore the rise in the price of the shares on the BSE is not known to the Company. They have been strictly following all the listing norms for disclosure, insider trading with the stock exchanges regularly and there is no pending compliance on their part.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1660.25 |
| Dr. Reddys Lab | 1219.20 |
| Cipla | 1230.95 |
| Zydus Lifesciences | 932.05 |
| Lupin | 2312.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: